Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dow Inc (DOW) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

DOW trades at $29.34, down 3.17% today, with technical indicators showing bearish momentum. The company faces fundamental challenges with negative net income margin of -3.13% and declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings beats provide some optimism, but cash flow from operations has weakened significantly from $7.5B in 2022 to $1.0B in 2025. The stock trades near the lower end of analyst price targets with consensus at $35.11.

DOW presents a mixed investment case with valuation metrics showing potential undervaluation (P/S 0.51) offset by profitability concerns. The chemical sector faces cyclical pressures, but recent dividend payments and earnings beats suggest operational resilience. Key risks include continued revenue decline and high debt levels approaching 30% of assets. Analyst sentiment remains cautious with only 33% buy ratings.